Active	Status	Sponsor type	Region	Phase	Filter
1 Active 3 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lifirafenib (BGB-283) / BeiGene
NCT03905148: Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors Jul 2021 - Dec 2021 : P1b data from trial in combination with BGB-283 for advanced solid tumors	Recruiting	1	105	US, RoW	Lifirafenib, BGB-283, mirdametinib, PD-0325901	BeiGene, SpringWorks Therapeutics, Inc.	Solid Tumor, Adult	09/25	02/26